GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
GRAIL, Inc. announced its management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3rd, at 7:35 a.m. ET. A live and replay webcast of the presentation will be available on the investor relations section of GRAIL’s website. GRAIL is a healthcare company focused on early cancer detection using next-generation sequencing and machine learning.
Patient Story: Kevin
Kevin McFarland, a firefighter, detected early-stage esophageal cancer through the Galleri test, despite having no symptoms. The test, offered by his fire department, identified a cancer signal, leading to successful minimally invasive surgery. Kevin's story highlights the importance of early detection and the support of his community and medical team.
Precision Trading with Grail Inc Com (GRAL) Risk Zones
This article provides a detailed analysis of Grail Inc Com (GRAL) for precise trading, highlighting weak near-term sentiment but an exceptional risk-reward setup targeting a 52.0% gain versus 0.3% risk. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes the current positive sentiment and encourages users to sign in for full access to real-time signals and institutional-grade analysis.
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL (NASDAQ:GRAL) reports continued growth in demand for its Galleri multi-cancer early detection test, despite recent NHS study headlines. The company's CFO highlighted strong clinical utility, physician adoption, and ongoing discussions with the NHS and FDA. GRAIL is also focusing on commercial growth through self-pay customers and strategic partnerships while preparing for potential reimbursement pathways.
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL (GRAL) reports continued strong demand for its Galleri multi-cancer early detection test, despite recent headlines concerning its NHS study. The company is preparing for the upcoming ASCO data presentation, has expanded its sales force, and actively continues discussions with the NHS regarding future implementation. Concurrently, GRAIL's FDA review is ongoing following their January submission, with the company confident in its performance data.
Baker Bros. reports 4.03M-share stake in GRAIL (NASDAQ: GRAL)
Baker Bros. Advisors and affiliated reporting persons have reported a beneficial ownership of 4,028,614 shares in GRAIL, Inc. (NASDAQ: GRAL), which constitutes a 9.8% stake of the 41,134,219 shares outstanding as of March 31, 2026. The holding is distributed across two funds, 667, L.P. and Baker Brothers Life Sciences, L.P. The filing also notes pre-funded warrants with a nominal exercise price of $0.001 are currently unexercisable due to a 4.99% ownership cap, though this cap can be increased to 19.99% under certain conditions.
GRAIL partners with Epic to broaden Galleri test access across US
GRAIL has announced a partnership with Epic, a leading healthcare software company, to integrate information on its multi-cancer early detection test, Galleri, into Epic's electronic health record system. This collaboration aims to provide healthcare providers with easier access to information about the Galleri test, facilitating broader adoption and accessibility for eligible patients across the US. The integration will streamline the ordering process and allow for better patient management.
GRAIL partners with Epic to broaden Galleri test access across US
GRAIL has announced a partnership with Epic, a leading health record software company, to integrate GRAIL's Galleri multi-cancer early detection test into Epic's electronic health record system. This collaboration aims to streamline the ordering, management, and results delivery of the Galleri test for healthcare providers, thereby broadening its accessibility across health systems in the United States. The integration is expected to enhance clinical workflows and support broader adoption of innovative cancer screening technologies.
How GRAIL’s Narrowed Q1 2026 Loss Profile Will Impact GRAIL (GRAL) Investors
GRAIL, Inc. reported Q1 2026 results with increased sales and revenue alongside a reduced net loss, indicating improved management of expenses and scaling of its multi-cancer early detection business. While these results slightly enhance the investment narrative, regulatory and reimbursement progress remains the primary near-term catalyst and the central risk is continued large losses and cash burn. The article emphasizes that investors should assess GRAIL's financial health considering these factors and current forecasts.
Number of shareholders of GRAIL, Inc. – NASDAQ:GRAL
The article provides a financial overview of GRAIL, Inc. (NASDAQ: GRAL), focusing on the number of shareholders. It indicates that the current data covers the period's value, change, and percentage change in shareholders, with market data provided by ICE Data Services and reference data by FactSet.
Farallon (GRAL) reports 2.68M shares and 571K warrants; 9.99% cap
Farallon Funds have amended their Schedule 13G/A, disclosing beneficial ownership in GRAIL, Inc. amounting to 2,682,663 shares and 571,021 pre-funded common stock purchase warrants. These warrants are assumed to be exercisable within 60 days, although they are subject to a 9.99% beneficial ownership limitation, which currently does not restrict their exercise. The filing details the various Farallon Funds and associated managing members who hold shared voting and dispositive power over these assets.
Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results
GRAIL, Inc. recently reported stronger-than-expected first-quarter results, with revenues exceeding estimates and smaller-than-anticipated losses per share. Analysts have slightly adjusted their sentiment, becoming more optimistic about future losses per share while maintaining revenue forecasts. Despite a projected slowdown in revenue growth, it is expected to align with the broader industry, and the average price target remains stable at US$68.57.
GRAIL to Present New Data on Multi-Cancer Early Detection Test
GRAIL is set to present new data from its NHS-Galleri and PATHFINDER 2 studies at the 2026 ASCO Annual Meeting, focusing on its Galleri multi-cancer early detection (MCED) test. These studies involve over 174,000 participants and aim to evaluate the test's performance, clinical utility, and safety. The NHS-Galleri trial is a randomized controlled study assessing population-level impact, while PATHFINDER 2 is an interventional study in North America for individuals with no clinical suspicion of cancer.
Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results
Following strong first-quarter results, GRAIL, Inc. (NASDAQ:GRAL) analysts have maintained their revenue forecasts for 2026 at US$181.4m and slightly reduced their loss per share expectations to US$10.72. The consensus price target remains constant at US$68.57, suggesting performance is in line with expectations. GRAIL's projected revenue growth of 22% annually until 2026 is expected to slow but remain comparable to the industry average.
[10-Q] GRAIL, Inc. Quarterly Earnings Report
GRAIL, Inc. has filed its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The report details the company's financial performance, including a net loss of $93.2 million, and highlights an increase in screening revenue driven by Galleri test sales. GRAIL also provides an outlook on its liquidity, capital resources, and ongoing efforts to secure FDA approval and broader reimbursement for its multi-cancer early detection test.
Earnings Flash (GRAL) GRAIL, Inc. Reports Q1 Revenue $40.8M, Vs. FactSet Est of $39.2M
GRAIL, Inc. (GRAL) announced its Q1 financial results, reporting revenue of $40.8 million. This figure exceeded the FactSet estimate of $39.2 million.
GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations
GRAIL, a healthcare company, anticipates a significant sales growth of 22%-32% for its Galleri multi-cancer early detection test in 2026. This projection comes as the company begins integrating its technology with Epic Aura, suggesting a strategic move to broaden accessibility and utilization of its diagnostic solution.
What GRAIL (GRAL)'s Narrowed Q1 Loss And Revenue Growth Means For Shareholders
GRAIL, Inc. reported a Q1 2026 sales of US$39.83 million and revenue of US$40.79 million, with a net loss of US$93.19 million, showing improvement over the previous year. This indicates progress in scaling its multi-cancer early detection business and controlling costs. The company's future investment narrative heavily relies on upcoming FDA review, payer coverage, and commercial partnerships to sustain its growth and manage its significant losses.
Press Release: GRAIL Reports First Quarter 2026 Financial Results
GRAIL announced its financial results for the first quarter of 2026. The press release details the company's financial performance during this period.
GRAIL (NASDAQ: GRAL) posts 28% Q1 growth and advances Galleri PMA
GRAIL (NASDAQ: GRAL) reported strong first-quarter 2026 results, with total revenue increasing 28% year-over-year to $40.8 million, largely driven by its Galleri test, which saw a 37% revenue growth and 50% increase in test volume. Despite remaining unprofitable with a net loss of $93.2 million, the company showed improved profitability metrics and ended the quarter with substantial liquidity of $823.1 million. GRAIL also advanced its Premarket Approval application for Galleri with the FDA and announced plans to integrate the test into Epic’s electronic health record platform for broader access.
GRAIL (GRAL) Price Target Decreased by 18.81% to 69.07
This article reports that the price target for GRAIL (GRAL) has been decreased by 18.81% to $69.07. The content provided is minimal, only stating this target reduction.
GRAIL executives head to Las Vegas conference, webcast starts May 12
GRAIL (Nasdaq: GRAL) announced it will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:40 a.m. PT. A live and replay webcast will be available via the investor relations site and archived for at least 30 days. This presentation offers investor visibility but does not introduce new financial or clinical data.
GRAIL (GRAL) Price Target Decreased by 18.81% to 69.07
This article reports that GRAIL (GRAL) has experienced a significant decrease in its price target. The target price has been lowered by 18.81% to 69.07. No further details about the reasons for this revision are provided.
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy
GRAIL, Inc. (NASDAQ: GRAL) has issued its 2026 proxy statement, detailing a planned leadership transition where President Joshua Ofman will succeed Robert Ragusa as CEO on June 1, 2026. Shareholders will vote on June 18, 2026, to elect two Class II directors and ratify Ernst & Young LLP as the auditor. The proxy statement also discloses 2025 executive compensation, with CEO Robert Ragusa receiving $8.09 million, CFO Aaron Freidin $3.13 million, and President Joshua Ofman $4.32 million.
Hims latest offering, Grail's Galleri cancer test, fails U.K. study
Hims & Hers' latest offering, Grail's Galleri multi-cancer early detection test, has failed to meet its primary endpoint in a large UK study. The Pathfinder 2 study, involving 140,000 asymptomatic individuals, did not demonstrate that the test significantly reduced late-stage cancer diagnoses compared to standard care. This outcome raises questions about the practical utility and widespread adoption of such tests.
GRAIL, Inc. Hits Day High with Strong 7.44% Intraday Surge
GRAIL, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, saw a significant 7.44% intraday surge, reaching a high of USD 54.95. This performance contrasts with its year-to-date decline but highlights strong financial improvements, including a 37.9% reduction in raw material costs, and robust institutional investor confidence. The company has also outperformed the S&P 500 over the past year.
GRAIL (GRAL) Price Target Decreased by 10.52% to 85.07
This article reports that the price target for GRAIL (GRAL) has been reduced by 10.52%, lowering it to $85.07. No further details are provided regarding the reasons for this adjustment or the firm responsible for the change.
Trading the Move, Not the Narrative: (GRAL) Edition
This article provides an AI-generated analysis of Grail Inc Com (NASDAQ: GRAL), focusing on trading strategies and risk management. It identifies near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with elevated downside risk. The analysis offers specific position, momentum breakout, and risk hedging trading strategies with entry zones, targets, and stop losses.
UBS AG (AMUB) sells $575K autocallable notes tied to GRAIL (GRAL) stock
UBS AG is offering $575,000 in Trigger Autocallable Yield Notes linked to GRAIL, Inc. (GRAL) common stock, set to mature on March 29, 2029. These notes provide a fixed annual coupon of 15.30% and feature an automatic call if GRAL's stock price reaches a certain threshold. Investors face exposure to the underlying stock's downside risk and UBS's credit risk, with potential for significant principal loss if the notes are not automatically called and GRAIL's stock falls below a specified downside threshold.
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into GRAIL, Inc. (GRAL) following a significant drop in its stock price. The investigation comes after GRAIL announced on February 19, 2026, that its NHS-Galleri trial did not meet its primary endpoint of statistically significant Stage III-IV reduction. The firm is encouraging shareholders who purchased GRAIL securities to contact them to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GRAIL, Inc. (GRAIL) (NASDAQ:GRAL) following a sharp drop in the company's stock price. The investigation comes after GRAIL announced on February 19, 2026, that the NHS-Galleri trial did not meet its primary endpoint of statistically significant Stage III-IV reduction. Shareholders are encouraged to contact the firm to assist with the investigation.
GRAIL to Announce First Quarter 2026 Financial Results
GRAIL, Inc. (Nasdaq: GRAL) announced that it will release its first quarter 2026 financial results after the market closes on Tuesday, May 5, 2026. Following the release, the company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The full announcement can be found on prnewswire.com.
GRAIL schedules May 5 webcast after Q1 results release
GRAIL (Nasdaq: GRAL) will release its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The company's announcement follows recent news regarding the integration of its Galleri test and a partnership with Superpower's preventive health platform.
GRAIL to present NHS-Galleri, PATHFINDER 2 data at ASCO meeting
GRAIL Inc. is set to present new data from its NHS-Galleri trial and PATHFINDER 2 study at the American Society of Clinical Oncology Annual Meeting. The presentations will detail findings on the Galleri multi-cancer early detection test, which screens for over 50 types of cancer. While GRAIL's stock has been volatile, the company maintains a strong financial position and is actively working to expand the reach of its test through collaborations and analyst coverage.
GRAIL to present NHS-Galleri, PATHFINDER 2 data at ASCO meeting
GRAIL Inc. (NASDAQ:GRAL) will present additional data from its NHS-Galleri trial and PATHFINDER 2 study at the American Society of Clinical Oncology Annual Meeting. The NHS-Galleri trial involved over 142,000 participants for early cancer detection, while PATHFINDER 2 studied the Galleri test in over 32,000 individuals with no clinical suspicion of cancer. Despite significant stock performance over the past year, GRAIL remains unprofitable, though it holds more cash than debt and liquid assets exceeding short-term obligations.
GRAIL to present NHS-Galleri, PATHFINDER 2 data at ASCO meeting By Investing.com
GRAIL Inc. announced it will present new data from its NHS-Galleri and PATHFINDER 2 studies at the upcoming ASCO Annual Meeting. The NHS-Galleri trial evaluated annual screening with the Galleri multi-cancer early detection test in over 142,000 participants in England, while PATHFINDER 2 enrolled over 32,000 participants in North America. Despite recent stock volatility, GRAIL maintains a strong financial position and is actively expanding the reach of its Galleri test through collaborations and seeking FDA approval.
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
GRAIL, Inc. will present new data from its NHS-Galleri trial and PATHFINDER 2 study at the 2026 ASCO Annual Meeting. These studies evaluate the Galleri multi-cancer early detection (MCED) test, with presentations covering primary randomized controlled trial results and safety and performance from a registrational study involving over 174,000 participants. The findings aim to strengthen the evidence supporting Galleri's clinical utility, performance, and safety in early cancer detection.
GRAIL, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
GRAIL, Inc., a small-cap biotechnology firm, is experiencing a revision in its stock evaluation due to its volatile market position. The company has seen significant stock price fluctuations from $118.53 to $25.56 over the past year, currently trading at $49.47. Despite outperforming the S&P 500 annually with an 86.68% return, GRAIL has faced a -42.2% year-to-date return, reflecting its mixed performance.
GRAIL, Inc. (GRAL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into GRAIL, Inc. (GRAL) following a significant drop in its stock price. This decline occurred after the company announced on February 19, 2026, that the NHS-Galleri trial's primary endpoint for reducing Stage III-IV cancers was not met. The firm is encouraging investors who purchased GRAIL securities to contact them to learn more about the potential claims and assist in the investigation.
GRAL SEC Filings - Grail Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Grail Inc. (GRAL) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. The platform offers AI-powered summaries, impact scoring, and sentiment analysis for each filing to help users understand key details such as private placements, equity distribution agreements, and strategic collaborations. It also notes recent filings for July 2025 and provides company ranking data.
GRAIL, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
GRAIL, Inc., a small-cap biotechnology firm, has seen significant stock fluctuations and recently underwent an evaluation revision. Despite a year-to-date decline of 46.69%, the company achieved a remarkable annual return of 100.62%, significantly outperforming the S&P 500, highlighting its volatile market presence. Technical indicators show a mixed picture with bearish weekly MACD but mildly bullish daily moving averages.
GRAIL (GRAL) director Steven Mizell takes $19.7K in deferred stock units
GRAIL, Inc. director Steven Mizell was granted 396 deferred stock units valued at $19,726.03, in lieu of cash director fees. The grant was based on a closing price of $49.79 per share on April 15, 2026, and the units vested immediately upon grant. Following this transaction, Mizell directly holds 37,071 shares of GRAIL common stock.
GRAIL (GRAL) director receives 408 deferred stock units as fees
GRAIL, Inc. director William J. Chase was granted 408 deferred stock units as compensation, valued at $20,342.47. These units, which vested immediately, were issued in lieu of cash director fees and were priced at $49.79 per share, based on the closing price on April 15, 2026. Following this transaction, Chase directly holds 37,211 shares of GRAIL common stock.
GRAIL (GRAL) director takes $31.4K in stock units instead of cash fees
GRAIL, Inc. director Gregory L. Summe received 631 deferred stock units, valued at $31,438.36, in lieu of cash director fees. The units, granted under the company’s 2024 Incentive Award Plan, vested immediately on April 15, 2026, increasing his direct holdings to 39,754 shares. This transaction highlights the company's use of equity-based compensation for its directors.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GRAIL, Inc. (GRAL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into GRAIL, Inc. (GRAL) following a sharp drop in the company's stock price. This decline occurred after GRAIL announced that its NHS-Galleri trial did not observe the primary endpoint of statistically significant Stage III-IV reduction. The firm is encouraging investors who purchased GRAIL securities to join the investigation.
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after the company's stock fell 50% following the failure of the NHS Galleri randomized trial to meet its primary endpoint. The law firm alleges that Grail's prior cash runway guidance extending into 2030 and burn-rate projections did not account for the risk of this trial failure, potentially misleading investors. Shareholders who incurred losses are encouraged to contact the firm for legal rights discussion.
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against GRAIL, Inc. (GRAL) following a sharp drop in stock price. This decline occurred after GRAIL announced on February 19, 2026, that its NHS-Galleri trial did not meet its primary endpoint of statistically significant Stage III-IV reduction. The firm is encouraging investors who purchased GRAIL securities to connect for more information and to assist in the investigation.
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Grail, Inc. (NASDAQ: GRAL) investors lost approximately 50% of their holdings after the NHS Galleri trial failed to meet its primary endpoint. This led to an investigation by Levi & Korsinsky, LLP, as the company had previously guided investors on cash burn and clinical milestones that may now be at risk. Shareholders who incurred losses are encouraged to contact the law firm to discuss their legal rights.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GRAIL, Inc. (GRAL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential claims against GRAIL, Inc. (GRAL) following a sharp drop in stock price. This decline occurred after GRAIL revealed that its NHS-Galleri trial did not meet its primary endpoint of statistically significant Stage III-IV reduction. The firm encourages investors who purchased GRAIL securities to join the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GRAIL, Inc. (NASDAQ:GRAL) due to a sharp drop in stock price following the announcement of NHS-Galleri trial results. The trial's primary endpoint of statistically significant Stage III-IV reduction was not observed. The firm encourages affected GRAIL investors to connect for further information and assistance with the investigation.
